06.12.2018 16:30:00

Press Release: Novartis investigational BYL719 -2-

delays or government regulation generally; global trends toward health

care cost containment, including government, payor and general public

pricing and reimbursement pressures; our ability to obtain or maintain

proprietary intellectual property protection; the particular prescribing

preferences of physicians and patients; general political and economic

conditions; safety, quality or manufacturing issues; potential or actual

data security and data privacy breaches, or disruptions of our

information technology systems, and other risks and factors referred to

in Novartis AG's current Form 20-F on file with the US Securities and

Exchange Commission. Novartis is providing the information in this press

release as of this date and does not undertake any obligation to update

any forward-looking statements contained in this press release as a

result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach nearly 1 billion people globally

and we are finding innovative ways to expand access to our latest

treatments. About 125,000 people of more than 140 nationalities work at

Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis and @NovartisCancer at

https://twitter.com/novartiscancer

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

[1] Juric D, Ciruelos EM, Rubovszky G et al. Alpelisib (ALP) +

fulvestrant (FUL) for advanced breast cancer (ABC): Phase 3 SOLAR-1

trial results. Presented at the San Antonio Breast Cancer Symposium

(SABCS) (Abstract #GS3-08) on December 6, 2018.

[2] Sabine V, Crozier C, Brookes C, et al. Mutational analysis of

PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant

multinational pathology study. Journal of Clinical Oncology.

2014;32:2951-2958.

[3] Miller TW, Rexer BN, Garrett JT, et al. Mutations in the

Phosphatidylinositol 3-Kinase Pathway: Role in Tumor Progression and

Therapeutic Implications in Breast Cancer. Breast Cancer Res. 2011.

[4] Saal LH, Johansson P, Holm K. Poor prognosis in carcinoma is

associated with a gene expression signature of aberrant PTEN tumor

suppressor pathway activity. PNAS. 2007;104(18):7564-7569.

[5] Fritsch C, Huang A, Chatenay-Rivauday A et al. Characterization of

the novel and specific PI3K alpha inhibitor NVP BYL719 and development

of patient stratification strategy for clinical trials. Molecular Cancer

Therapeutics.2014; 13(5):1117-1129.

*Qiagen is a registered trademark of QIAGEN N.V.

**Foundation Medicine is a registered trademark of Foundation Medicine,

Inc.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Julie Masow

Novartis Global Media Relations Novartis Oncology Media Relations

+41 61 324 7999 (direct) +1 862 579 8456 (mobile)

+41 79 593 4202 (mobile) julie.masow@novartis.com

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2228081/874878.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

December 06, 2018 10:30 ET (15:30 GMT)

Analysen zu Novartis AG (Spons. ADRS)mehr Analysen

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
pagehit